New therapeutic strategies in HER2-positive breast cancer

xlomafota13 shared this article with you from Inoreader New therapeutic strategies in HER2-positive breast cancer Via Association française pour l'étude du cancer Bull Cancer. 2021 Jun 15:S0007-4551(21)00215-0. doi: 10.1016/j.bulcan.2021.04.015. Online ahead of print. ABSTRACT Breast cancer with HER2-amplification accounts for 20% of breast cancers. The management of patients has dramatically changed with the advent of anti-HER2 treatment, especially the monoclonal antibodies since 2000 in the metastatic and (neo)-adjuvant setting, leading to an improvement of patient outcomes. If therapeutic arsenal has been gradually enhanced with the targeting of HER receptors family, resistances to these treatments are observed, hence the development of new therapeutic strategies. This review provides an updated look of novel therapeutic strategies in HER2-positive breast cancer, as well as future perspectives, both in the adjuvant and metastatic setting. PMID:34144793 | DOI:10.1016/j.bulcan.2021.04.015 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.